{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/allergic-rhinitis/prescribing-information/oral-antihistamines/","result":{"pageContext":{"chapter":{"id":"449809a3-a714-573e-a21f-8e4295eb984e","slug":"oral-antihistamines","fullItemName":"Oral antihistamines","depth":2,"htmlHeader":"<!-- begin field d29aefe6-b1ca-492b-acf0-b924be690f3b --><h2>Oral antihistamines</h2><!-- end field d29aefe6-b1ca-492b-acf0-b924be690f3b -->","summary":"","htmlStringContent":"<!-- begin item 5f946810-f854-4768-a683-82464207eb03 --><!-- end item 5f946810-f854-4768-a683-82464207eb03 -->","topic":{"id":"e84371ef-9d30-56df-8358-1520fb2c324f","topicId":"0473d89c-2999-40d1-911f-d265b4bd3942","topicName":"Allergic rhinitis","slug":"allergic-rhinitis","lastRevised":"Last revised in September 2018","chapters":[{"id":"5fa28a05-233b-5de6-aee8-ea0327f3c7d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ea1f0c07-a5f8-599b-9b96-71ef8590b2a6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"99b142c6-9593-51c7-9c86-7c8a537a3b8c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"67cd9666-b198-574f-9fbf-cd740a7d8c3e","slug":"changes","fullItemName":"Changes"},{"id":"7d544db5-f3b7-5709-a2ae-076455d76d20","slug":"update","fullItemName":"Update"}]},{"id":"392391e3-b09a-5cab-ae2a-040eb039abd9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"292568d8-a1f5-5b8f-a13d-f3c014fa8e95","slug":"goals","fullItemName":"Goals"},{"id":"2f7129b7-e08b-5e5f-997c-4b661ce0a778","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8062582a-18e3-58d5-a8cb-f9689e259444","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1e562233-ae40-5755-abc7-71551f4cea02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ccab909c-169d-52aa-ac0a-9d425f89a99c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"37d61d5d-e2f1-58ef-9c6a-27c4011784f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84432cb8-00ce-599e-9e05-3493755dacd6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f59296af-8e0a-509d-b8f3-692efd2bdb92","slug":"definition","fullItemName":"Definition"},{"id":"37020833-afb2-529a-975a-1f1a7a5db2ef","slug":"causes","fullItemName":"Causes"},{"id":"962f75f0-d73d-5c7c-aaf4-d08fc672e6be","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ab993d04-4c7b-59cd-9e56-2e0ef7fdc9db","slug":"complications","fullItemName":"Complications"},{"id":"68b348fd-2864-5da4-8687-6d8c25004f1b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"80c9e7d3-3315-55b9-98fb-2261b95a1b5c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3cc3ef09-2238-5504-8781-48914ad6a4c9","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5a3f0e38-3f88-5049-beaa-f4cb26499dc6","slug":"assessment","fullItemName":"Assessment"},{"id":"5bd413c7-0398-5b71-acad-a5699c7c703b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9b8b1dfa-dfda-5292-a329-64d2c435a006","fullItemName":"Management","slug":"management","subChapters":[{"id":"a132cc60-bb1b-5679-8eda-db080a1e772a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"760f3c4d-0984-5865-acbe-65d470f66518","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a47a2aa5-0821-5bf5-987b-2397ac2c982f","slug":"intranasal-antihistamines","fullItemName":"Intranasal antihistamines"},{"id":"449809a3-a714-573e-a21f-8e4295eb984e","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"5507fb81-aa18-5a21-b619-8db3c3c78e80","slug":"intranasal-cromones","fullItemName":"Intranasal cromones"},{"id":"5102b868-dccf-58c1-b6c7-3a59a24c6602","slug":"intranasal-decongestants","fullItemName":"Intranasal decongestants"},{"id":"623ba003-b473-5be2-bc25-e438f1500f7c","slug":"intranasal-anticholinergics","fullItemName":"Intranasal anticholinergics"},{"id":"c871daa0-d649-59f1-b13c-79ab64e7083e","slug":"oral-leukotriene-receptor-antagonists","fullItemName":"Oral leukotriene receptor antagonists"}]},{"id":"f3877d58-da5a-5655-8752-49e87f3a410b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"87371e7f-8741-54ef-9af6-339f8f0b9285","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"318f5be9-46cf-5fb9-b28c-7ebb4a901904","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49c3da95-9d4f-5a93-a7ca-e71965fcb981","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"33a2085c-95d6-5004-8f1f-50a08684c638","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b1a0d4a-fd5e-5b81-9293-5b2f004871cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"735b627c-7d7e-58b8-8196-b4972220342b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"92889a85-b6e7-58f3-9f09-eae6ca76386c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"760f3c4d-0984-5865-acbe-65d470f66518","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"46711e39-82e4-5370-a18e-80f953e96f49","slug":"dose-regimens","fullItemName":"Dose regimens","depth":3,"htmlHeader":"<!-- begin field f0216d6b-0877-4508-896d-a96b011471fd --><h3>Dose regimens</h3><!-- end field f0216d6b-0877-4508-896d-a96b011471fd -->","summary":"","htmlStringContent":"<!-- begin item f95b0572-d203-436a-b3a1-a96b011471cf --><!-- begin field 72b011ba-b6b2-4612-9af1-a96b011471fd --><ul><li><strong>Cetirizine hydrochloride is not licensed for use in children under 2 years of age.</strong> A suggested dose regimen is:<ul><li>Children aged 1 year — 250 micrograms/kg twice daily (off-label).</li><li>Children aged 2–5 years — 2.5 mg twice daily.</li><li>Children aged 6–11 years — 5 mg twice daily.</li><li>Children aged 12 and over, and adults — 10 mg once daily.</li></ul></li><li><strong>Loratadine is not licensed for use in children under 2 years of age.</strong> A suggested dose regimen is:<ul><li>Children aged 2–11 years and body weight up to 31 kg — 5 mg once a day.</li><li>Children aged 2–11 years and body weight 31 kg and over — 10 mg once a day.</li><li>Children aged 12 years and over, and adults — 10 mg once a day.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>] </p><!-- end field 72b011ba-b6b2-4612-9af1-a96b011471fd --><!-- end item f95b0572-d203-436a-b3a1-a96b011471cf -->","subChapters":[]},{"id":"acaaa552-09cc-5d24-a05d-9e3375762d25","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8858b94a-a273-4c52-ace9-d7df18c958ce --><h3>Contraindications and cautions</h3><!-- end field 8858b94a-a273-4c52-ace9-d7df18c958ce -->","summary":"","htmlStringContent":"<!-- begin item 8f9d7505-6b49-4771-9fb2-aec049f14a9e --><!-- begin field 76b8b0cd-b9f4-48a8-b3da-77eb20be7a5a --><ul><li><strong>Do not prescribe cetirizine to people with:</strong><ul><li>Severe renal impairment — estimated glomerular filtration rate (eGFR) less than 10 mL/min/1.73 m<sup>2</sup>.</li></ul></li><li><strong>Prescribe cetirizine with caution to people with:</strong><ul><li>Epilepsy.</li><li>Renal impairment<ul><li>If the eGFR is 30–50 mL/min/1.73 m<sup>2</sup>, use half the normal dose.</li><li>If the eGFR is 10–30 mL/min/1.73 m<sup>2</sup>, use half the normal dose and reduce the dose frequency to alternate days.</li></ul></li></ul></li><li><strong>Prescribe loratadine with caution to people with:</strong> <ul><li>Severe hepatic impairment — reduce the dose frequency to alternate days.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>] </p><!-- end field 76b8b0cd-b9f4-48a8-b3da-77eb20be7a5a --><!-- end item 8f9d7505-6b49-4771-9fb2-aec049f14a9e -->","subChapters":[]},{"id":"809239aa-da2c-5ef2-993f-78b8e7fcc4bf","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3e2f7213-1767-48df-8a64-0e0b040e4e1b --><h3>Adverse effects</h3><!-- end field 3e2f7213-1767-48df-8a64-0e0b040e4e1b -->","summary":"","htmlStringContent":"<!-- begin item 29faef44-adc1-463d-bc7b-78d88bf63a32 --><!-- begin field 52953553-71e8-413c-bb7d-facf296fd125 --><ul><li><strong>Possible adverse effects of cetirizine and loratadine include:</strong><ul><li>Blurred vision, dry mouth, headache, diarrhoea, psychomotor impairment, urinary retention.</li><li>Drowsiness (frequency not known) — cetirizine and loratadine cause less sedation and psychomotor impairment than first-generation antihistamines, because they penetrate the blood brain barrier to a lesser extent.<ul><li>Advise people taking non-sedating antihistamines that some people may experience sedation, which may affect their ability to drive, and that the sedative effects are enhanced when combined with alcohol.</li></ul></li><li>Angio-oedema, arrhythmias, blood disorders, bronchospasm, confusion, convulsions, depression, dizziness, extrapyramidal effects, hypersensitivity reactions, hypotension, liver dysfunction, photosensitivity reactions, rashes, sleep disturbances, tremor, angle-closure glaucoma (in adults).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]</p><!-- end field 52953553-71e8-413c-bb7d-facf296fd125 --><!-- end item 29faef44-adc1-463d-bc7b-78d88bf63a32 -->","subChapters":[]},{"id":"329c88e7-16e3-5ff7-8aa6-4df6607e8c89","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b6451096-0053-4a48-9c13-a96800db870d --><h3>Drug interactions</h3><!-- end field b6451096-0053-4a48-9c13-a96800db870d -->","summary":"","htmlStringContent":"<!-- begin item 55a05b34-d755-4a15-bd49-a96800db860c --><!-- begin field 2f351ac1-be85-46cc-af29-a96800db870d --><p><strong>Possible drug interactions with cetirizine and loratadine include:</strong></p><ul><li><strong>Betahistine</strong> — cetirizine and loratadine are predicted to decrease the effects of betahistine.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]</p><!-- end field 2f351ac1-be85-46cc-af29-a96800db870d --><!-- end item 55a05b34-d755-4a15-bd49-a96800db860c -->","subChapters":[]},{"id":"58b8dff0-a08b-5e03-966a-2a378f7f0d60","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field a08541a5-ef35-4048-8fa1-a96b011220d5 --><h3>Pregnancy and breastfeeding</h3><!-- end field a08541a5-ef35-4048-8fa1-a96b011220d5 -->","summary":"","htmlStringContent":"<!-- begin item b6968ff8-7e87-4dba-871f-a96b01121fcb --><!-- begin field d4972964-599f-4949-81ef-a96b011220d5 --><h4>Pregnancy</h4><ul><li>There are limited data on the use of cetirizine and loratadine in pregnancy, however there is no evidence of harm. </li><li>The manufacturer advises these drugs should be used with caution in women who are pregnant.</li></ul><h4>Breastfeeding</h4><ul><li>Cetirizine and loratadine are excreted in breast milk, and large doses or more prolonged use may inhibit lactation or cause drowsiness and other adverse effects in the infant.<ul><li>Small, occasional doses are not expected to cause adverse effects. </li></ul></li><li>The manufacturer advises caution if used in women who are breastfeeding.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">LactMed, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>] </p><!-- end field d4972964-599f-4949-81ef-a96b011220d5 --><!-- end item b6968ff8-7e87-4dba-871f-a96b01121fcb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}